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Abstract
Obesity confers an increased risk for cardiovascular renal diseases, diabetes mellitus,
nonalcoholic steatohepatitis, musculoskeletal disorders, and cancers. Prokineticin‐2 is
a peptide hormone, which exists as both a circulating hormone system and a local
paracrine‐signaling mechanism within various tissues including the brain, kidney, and
adipose. It acts on the G‐protein‐coupled receptors (GPCRs) PKR1 and PKR2. The role
of  prokineticin‐2  in  the  central  nervous  system  is  the  control  of  food  intake.  Its
anorexigenic effect is at least partly through the hypothalamic melanocortin system.
Prokineticin‐2  also  prevents  adipose  tissue  expansion  by  limiting  preadipocyte
proliferation  and  differentiation  capacity.  Prokineticin‐2  signaling  is  important  for
insulin capillary passages. It also regulates heart and kidney development and function.
Here, we discuss a new obesity peptide prokineticin signaling in central regulation of
food intake, adipocyte tissue development, and cardiovascular function. Prokineticin
may play a key role in the association between obesity and cardiovascular diseases. We
also outline the potential of prokineticin receptor‐1 as target for the treatment of obesity
and cardiovascular diseases.
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1. Introduction
Obesity is a major health problem and an increased risk factor that worsens cardiovascular
events leading to higher morbidity and mortality. [1] Several cardiovascular diseases can also
occur due to structural and functional changes of the myocardium through excess fat deposition
and other mechanisms related to obesity [2]. However, the mechanisms of relation between
obesity and cardiovascular events are unclear. Nevertheless, pharmacological therapy for
obesity has great potential to improve cardiovascular problems. Several anorexcigenic peptides
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have been studied as potential drugs in the treatment of obesity [3]. Recent evidence showed
that some brain regions may not only be involved in food intake regulation but also play an
important role in the regulation of cardiovascular blood homeostasis [4]. The rising prevalence
of both obesity and heart failure make this association an important target for prevention.
Therefore, it is important to determine the common mechanisms regulating both obesity and
cardiovascular events. Identification of signaling pathways linking obesity and cardiovascular
disease is important for the development of novel therapeutics. Here, we summarize the current
information on the role of anorexigenic peptide prokineticin in obesity and cardiovascular renal
diseases, emphasizing prokineticin receptor‐1 signaling in these events.
2. Prokineticins and their receptors
Prokineticins are anorexigenic and angiogenic hormones. Because of the structural, signaling
and functional similarities, prokineticins are considered as cytokines/chemokines [5]. They are
released principally by macrophages and reproductive organs [6]. Recently, prokineticin is
considered as an adipokine because a high level of prokineticins has been found in obese
human WAT [7]. These small peptides (80–120 amino acids) are called prokineticins, because
these molecules were first identified as potent contractile factors in the gastrointestinal tract
[8]. Two isoforms of prokineticins have been identified: prokineticin‐1 and prokineticin‐2.
Prokineticin‐1 has been originally called as endocrine gland‐derived vascular endothelial
growth factor (EG‐VEGF), [9] because of its functional similarity to VEGF. Prokineticin‐2 is
also called as Bv8. Both of these peptides are 45% identical with highly conserved N‐terminal
AVITGA motif essential for their biological activity [6, 10]. Prokineticin activity is mediated
by two G‐protein‐coupled receptors, PKR1 and PKR2 [11].
2.1. Prokineticin‐2 is an anorexigenic peptide
Circulating hormones and nutrients are integrated to mediate the regulation of short‐term and
long‐term dietary intakes in the hypothalamus. A feeding and energy homeostasis control
center in the hypothalamus is called as arcuate nucleus (ARC) [12, 13]. The ARC integrates
most of the peripheral hormonal signals including leptin, insulin and ghrelin. The ARC has
two major subpopulations of primary neurons that express neurohormones with opposing
effects on food intake. ARC neurons that release the proopiomelanocortin (POMC)‐derived
peptide alpha‐melanocyte‐stimulating hormone (α‐MSH) and cocaine‐ and amphetamine‐
regulated transcript (CART) peptide potently reduce food intake [13, 14]. However, neuro‐
peptide Y (NPY)‐producing neurons in the ARC stimulate food intake.
Prokineticin‐2 is involved in the control of food intake and of fat mass through actions in the
ARC in the hypothalamus [15]. PKR1 receptor is expressed on both NPY/AgRP and POMC/
CART neurons. Intracranial injection of prokineticin‐2 in rats strongly decreases food intake.
Controversy, anti‐prokineticin‐2 antibody increases food intake. Anorexigenic effect of pro‐
kineticin‐2 is mediated at least partly via the hypothalamic ARC melanocortin system. Proki‐
neticin‐2 increases the release of alpha‐MSH from ex vivo hypothalamic explants. Recently,
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PKR1 has been shown as the first non‐melanocortin GPCR to be regulated by the melanocor‐
tin receptor accessory protein 2 (MRAP2). Indeed, MRAP2 significantly and specifically in‐
hibits PKR1 signaling [16].
Peripheral administration of prokineticin‐2 reduces food intake and body weight in both
lean mice and diet‐induced obesity models [17]. This effect of prokineticin‐2 is not evident
when appetite is increased or feeding behavior is promoted. Hypothalamic prokineticin‐2
levels were found extremely high in the early neonatal period. However, a decreased level of
prokineticin‐2 was evident under fasting conditions [18]. Prokineticin‐2‐knockout mice be‐
came obese at the late age. Humans with the inactivating mutations of prokineticin‐2 gene
are also obese [17, 19]. The anorectic effects of prokineticin‐2 are abolished by PKR1 antago‐
nists and not observed in mice lacking PKR1 [17]. Thus, the anorectic effects of prokineticin‐
2 in the hypothalamus are mediated by PKR1.
2.2. Prokineticin in the development of obesity
The mechanisms underlying the development of obesity include the hypertrophy and/or
hyperplasia of adipocytes, adipose tissue (AT) inflammation, impaired extracellular matrix
remodeling and fibrosis together with an altered secretion of adipokines [20]. AT expansion
involves two distinct mechanisms: an enlargement in adipose cells and an increase of adipo‐
cytes number [21]. Differentiated adipocytes are post‐mitotic and therefore hyperplasia is the
result of increased de novo adipocyte formation (adipogenesis). Impaired adipogenesis is
associated with insulin resistance [22]. The balance between proliferation and differentiation
of preadipocytes and adipocyte apoptosis or necrosis determines adipocyte number.
Prokineticin‐2 levels were found to be high in obese human WAT [7]. Prokineticin‐2 suppresses
AT expansion by two distinct mechanisms: the central regulation of food intake and limiting
preadipocyte proliferation and differentiation. The central regulation of body weight is
counteracted by loss of PKR1 in adipose tissue in mice. Indeed, an abnormally excessive
abdominal fat mass accumulation was observed in these mice where the PKR1 specifically
deleted in the adipocytes (PKR1ad‐/‐) [7]. The formation of new adipocytes in both PKR1 null
and PKR1ad‐/‐ mice was resulted from an acceleration of preadipocyte proliferation and
differentiation. AT proliferative phenotype has switch to AT hypertrophic phenotype when
these mice were treated with a high‐fat diet, implicating high calorie intake is involved in the
conversion of hyperplasia to hypertrophy. In isolated preadipocytes, PKR1 activation sup‐
presses proliferation and adipogenic differentiation [38].
Both PKR1null and PKR1ad‐/‐ mice display abdominal obesity [7] However, only PKR1null mice
have peripheral obesity with a diabetes‐like syndrome. Thus, non‐adipocyte PKR1‐mediated
events contribute to the development of a diabetes‐like syndrome. Indeed, endothelial‐specific
PKR1‐knockout mice (PKR1ec‐/‐) [23] had insulin resistance in adipocytes. In PKR1ec‐/‐ adipo‐
cytes, insulin cannot promote normal fat storage, resulting in excess circulating free fatty acids
that, in turn, further contribute into insulin resistance in muscle, leading to diabetes‐like
syndrome. However, it seems that PKR1 has no direct effect on fat deposition in adipocytes.
PKR1ad‐/‐ mice did not have severe accumulation of fat tissue in their adipocytes. Since
adipocytes are not created from other adipocytes, but they arise from precursor cells (preadi‐
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pocytes), PKR1 suppress the ability of these precursor cells to become adipocytes (Figure 1)
[7]. The expansion and metabolism of the adipose tissue are the major problem in obesity.
Figure 1. Prokineticin‐2/PKR1 signaling may act as a new connector between development of obesity, diabetes and car‐
diovascular diseases. Prokineticin‐2/PKR1 signaling in central nervous system (CNS) regulates food intake. Prokineti‐
cin‐2 released from adipocytes controls preadipocyte conversion to adipocyte via PKR1 signaling. Prokineticin‐2/PKR1
signaling promotes survival of cardiomyocytes and angiogenesis and involved in neovascularization by activating car‐
diac progenitor cells. Prokineticin‐2/PKR1 signaling contributes to heart and kidney development as well as kidney
function. Whether this signaling involves heart and kidney regulation through CNS remains to be studied.
2.3. Prokineticin in insulin resistance
The endothelium is essential for insulin transcapillary delivery to the skeletal muscle interstiti‐
um. This process is the rate‐limiting step in insulin‐stimulated glucose uptake. [24] The impair‐
ment of insulin delivery process contributes to insulin resistance [25]. On the other hand, insulin
resistance leads to endothelial dysfunction [26]. Thus, the vascular endothelium is a potential
therapeutic target for the prevention of insulin resistance and related complications [27].
Endothelium‐specific PKR1‐knockout mice (PKR1ec‐/‐) display impaired capillary formation
and low transcapillary insulin uptake [23]. Impaired insulin delivery and signaling in endo‐
thelial cells (ECs) has been observed in cases of insulin resistance with type 2 diabetes and
obesity. Endothelial cells overexpressing PKR1 promotes insulin transendothelial uptake [9]
and angiogenesis [28]. PKR1ec‐/‐ mice display lipodystrophy due to poor capillary formation in
the AT. Lipodystrophies, involving a loss of WAT, cause hyperphagia and peripheral insulin
resistance [29].
As a summary, prokineticin regulates appetite (effects in central nervous system (CNS)) and
suppresses adipocyte expansion (direct effect on adipocyte tissue), promotes normal fat stor‐
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age (endothelial‐dependent effect) and increases insulin sensitivity. Therapeutic strategies
targeting PKR1 could be important to treat obesity and obesity‐associated insulin resistance.
2.4. Prokineticin in cardiovascular regulation
Obesity is both an independent risk factor and a risk marker for the development of asymp‐
tomatic and symptomatic coronary artery disease, heart failure and atrial fibrillation [2]. The
relationship between obesity and cardiovascular diseases may be associated with hemody‐
namic and anatomic cardiovascular changes related to excess body mass [30]. However, the
relationship can also be mediated by obesity‐related metabolic, inflammatory and neurohor‐
monal changes.
Altered expression of prokineticins and their receptors has been implicated in the development
of a number of pathological cardiac conditions, including heart failure [31]. Prokineticins and
their receptors have been identified as an important cardiovascular‐signaling system especially
cardiac cell commitment and cell‐to‐cell communications [32].
PKR1‐mediated signaling contributes to cardiomyocyte survival and adult heart repair. PKR1
activates Akt in cardiomyocyte to protect these cells against hypoxia‐mediated apoptosis [33].
Transgenic (TG) mice‐overexpressing PKR1 in the cardiomyocytes (TG‐PKR1) had an in‐
creased number of epicardial‐derived progenitor cells (EPDCs), with an increase of capillary
density and coronary arterioles. [32] The cardiac‐PKR1 signaling up‐regulates its own ligand
prokineticin‐2 to stimulate the EPDC differentiation into endothelial and smooth muscle cells
to promote neovasculogenesis [32]. However, cardiomyocyte‐PKR1 is essential for cardio‐
myocyte survival and contractility. PKR1null mice displayed cardiomyocyte‐contractile defects
and apoptosis partially due to lack of PKR1 signaling in cardiomyocytes. [34]
In endothelial cells (ECs), PKR1 activates Akt and MAPK to promote proliferation, migration
and angiogenesis. In agreement with the in vitro findings, the specific loss of PKR1 from mouse
ECs resulted in defective angiogenesis, leading to necrosis/apoptosis in the surrounding
tissues in several organs, including the heart and kidneys [23].
There was significantly less capillary formation in adult PKR1ec‐/‐ hearts. The posterior walls
of PKR1ec‐/‐ hearts were thinner, which was due to the loss of capillary formation and a high
level of apoptosis [23]. The remaining viable heart muscle is subject to greater biomechanical
stress, triggering hypertrophy [23]. Shortening fractions (indicators of left ventricular contrac‐
tility) were progressively reduced in mutant mice. PKR1ec‐/‐ hearts displayed EC deregulation,
capillary refraction, apoptosis, fibrosis and ectopic lipid deposition, abnormal insulin signaling
in hearts resulting in impaired diastolic function.
The ECs of hearts exhibited severely decreased FICT‐insulin uptake, indicating defective
transcapillary transport of insulin in the vascular wall of these mice. Isolated ECs from the
mutant cardiac and renal tissues exhibited very little insulin uptake, confirming that the loss
of PKR1 from EC decreased insulin transport [23]. Overexpressing PKR1 in these ECs pro‐
moted fluorescein isothiocyanate (FITC)‐insulin passage. Indeed, the primary defect linking
insulin resistance and endothelial dysfunction is believed to be nitric oxide deficiency of
endothelial origin [35]. In agreement, insulin uptake and insulin‐mediated eNOS activation
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were impaired in all mutant ECs. Similarly, altered eNOS activation and low insulin action
have recently been demonstrated in the endothelium of patients with diabetes mellitus [36].
Thus, impaired insulin delivery to ECs may lead to defective NOS and eNOS activation in
PKR1ec‐/‐ aortas, consequently impairing endothelium‐dependent relaxation. These data
highlight the role of PKR1 as a positive regulator of insulin uptake [37].
PKR1 signaling also contributes to heart development. In developing heart, PKR1 regulates
epicardial‐mesenchymal transition (EMT) to form epicardial‐derived progenitor cell (EPDC)
[38]. Genetic ablation of PKR1 in epicardium leads to ventricular hypoplasia and septal defects
during embryogenesis. Impaired vasculogenesis in these mice is due to impaired EPDC
proliferation as well as a defective EPDC differentiation into endothelial and smooth muscle
cell type. PKR1 in EPDCS activates Akt signaling, changes cell morphology, actin cytoskeleton
remodeling and EMT gene expression profile. Epicardial‐PKR1 contributes to cardiomyocyte,
proliferation and rhythmicity in a paracrine pathway.
2.5. Prokineticin in renal development and function
Global PKR1‐knockout mice have peripheral obesity accompanied by a diabetes‐like syn‐
drome at the late ages (36 weeks old) [7], mainly due to endothelial dysfunction and impaired
adipose tissue functions [37]. These mice also exhibited cardiomegaly, severe interstitial
fibrosis and cardiac dysfunction under the stress conditions. These mice also displayed
impaired renal tubular dilation, reduced glomerular capillaries, urinary phosphate excretion
and proteinuria [34].
Similarly, endothelial‐specific PKR1‐knockout mice (PKR1ec‐/‐) also displayed dilatation of
Bowman's spaces in most glomeruli, a compact glomerulus, fibrosis and enlarged tubular
structures with a swollen necrotic nucleus, abnormal mitochondria and aberrant organization
of podocytes. Abnormal tubular function with higher levels of absolute renal phosphate (Pi)
excretion in the PKR1ec‐/‐ mice is due to lower levels of sodium‐calcium and sodium phosphate
exchanger. The morphological changes in the PKR1ec‐/‐ kidneys were associated with higher
levels of apoptosis and impaired insulin signaling and lipid accumulation. Mutant mice
displayed high levels of creatinine clearance and proteinuria. [34] Endothelial dysfunction
resulted from loss of PKR1 signaling partially underlies the pathological features of heart and
kidney.
PKR1 signaling in kidney is essential for nephron development during embryogenesis [38].
Recently, it has been shown that mutant mice with targeted PKR1 gene disruptions in nephron
progenitors exhibited partial embryonic and postnatal lethality due to hypoplastic kidneys
with premature glomeruli and necrotic nephrons. Kidney developmental defects in these mice
are manifested in the adult stage as renal atrophy with glomerular defects, nephropathy and
uremia. Thus, PKR1 is necessary for renal mesenchymal‐epithelial transition (MET) that is
involved in the formation of renal progenitors, regulating glomerulogenesis toward forming
nephrons during kidney development. Indeed, PKR1 through NFATc3 modifies MET proc‐
essing to the development of nephron.
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3. Conclusion
PKR1 signaling has various beneficial effects, e.g., central regulation of appetite, the sup‐
pression of adipocyte mass and insulin‐sensitizing effects on skeletal muscle and other
tissues, cardiac regenerative effects and regulation of kidney function. This has attracted
considerable interest in the possible use of this receptor as a target for treatments combating
obesity, diabetes and cardiovascular diseases. Intracardiac PKR1 gene transfer improved
survival rate and heart functions after myocardial infarction [33]. Since PKR2 has been found
to contribute to vascular leakage and hypertrophic cardiomyopathy [39], several laboratories
are focused on the discovery of PKR1 agonist. Recently, PKR1 non‐peptide agonist has been
identified [40]. PKR1 agonist prevents cardiac lesion formation and improved cardiac
function after myocardial infarction in mice, promoting proliferation of cardiac progenitor
cells and neovasculogenesis. PKR1 agonist in treatment strategies of metabolic disease
remains to be studied.
How prokineticin‐2 contributes to the AT remodeling [41], how it modulates the interaction
between the adipocytes, macrophages and endothelial cells to regulate AT expansion [42]
remains also to be determined. Circulating prokineticin levels in obese, diabetic and heart
failure patients remain to be explored.
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